The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Subscribe To Our Newsletter & Stay Updated
